复星医药:公司制药业务创新药品收入超人民币37亿

互动易
11 Feb

有投资者向复星医药提问, 公司销售收入中仿制药,原研药,化学制剂,单抗各占比多少?公司回答表示,投资者您好!2024年上半年,公司制药业务实现收入人民币146.77亿,其中创新药品收入超人民币37亿(含奕凯达),创新药品收入占制药板块收入超过25%。公司制药业务产品主要包括五大治疗领域的制剂产品,以及原料药和中间体等。结合实际情况,按治疗领域划分的制剂产品的收入情况可参见年报、半年报“主营业务分析...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10